EMA Adopts a Positive Opinion for Biosimilar Denosumab By Ogkologos - May 28, 2025 830 0 Facebook Twitter Google+ Pinterest WhatsApp Jubereq is a biosimilar of Xgeva, which was authorised in the EU in 2011 Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Adding Pembrolizumab To Preoperative Radiotherapy and Surgery Improves DFS for Patients... December 2, 2024 Bus Driver Finds Out Teen With Cancer Can’t Afford Prom &... June 19, 2019 ESMO Announces Results of 2025 Elections June 14, 2025 Large DFS Benefit from Adjuvant Cemiplimab Among Patients at High Risk... June 18, 2025 Load more HOT NEWS Adjuvant Nivolumab Prolongs DFS in Patients with Resected Osophageal or Gastroesophageal... Six Years of Adjuvant Imatinib Improves DFS Over Three Years Treatment... p53 Mutations May Differentially Affect Survival of Patients with mCRC Based... Overall Breast Cancer Incidence Down Since 1999, Rates Increase for Women...
